Meeting Banner
Abstract #2582

Assessment of IDH1 Mutation Status and MGMT Promoter Methylation Status of Gliomas Using DWI, IVIM and DKI

Yan Xie1, Shihui Li1, Nanxi Shen1, Weiyin Vivian Liu2, and Wenzhen Zhu1
1Department of Radiology, Tongji Hospital, Tongji Medical College, HUST, Wuhan, China, 2MR Research, GE Healthcare, Beijing, China

The purpose of this study was to evaluate the efficacy of conventional diffusion weighted imaging (DWI), intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) in assessing IDH1 mutation status and MGMT promoter methylation status in gliomas. In lower-grade gliomas, diffusion MRI parameters were able to significantly distinguish the mutation status of IDH1 and the methylation status of MGMT promoter, which is helpful for predicting prognosis and sensitivity to alkylating chemotherapeutic agents of patients. However, in glioblastomas, there was no significant difference between mutant and wild-type IDH1 as well as methylation and unmethylation status of the MGMT promoter.

This abstract and the presentation materials are available to members only; a login is required.

Join Here